Antithrombotic drug therapy for IgA nephropathy: A meta analysis of randomized controlled trials

Internal Medicine

Volumn 50, Issue 21, 2011, Pages 2503-2510

  Liu, Xiu Juan ^a,b   Geng, Yan Qiu ^b   Xin, Shao Nan ^c   Huang, Guo Ming ^a   Tu, Xiao Wen ^a   Ding, Zhong Ru ^a   Chen, Xiang Mei ^b  

^a The 94th Hospital of PLA   (China)

^b GENERAL HOSPITAL OF PEOPLE'S LIBERATION ARMY   (China)

^c Nanchang Military Academy of Chinese PLA   (China)

Author keywords

Antithrombotic agents; Glomerulonephritis; IgA nephropathy; Meta analysis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BENAZEPRIL; DIPYRIDAMOLE; FERULIC ACID; PLACEBO; UROKINASE; WARFARIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PROTEINURIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

BENZAZEPINES; FIBRINOLYTIC AGENTS; GLOMERULONEPHRITIS, IGA; HUMANS; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80455168027     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5971     Document Type: Article

References (37)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 347: 738-748, 2002.
2. Schena FP. Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for the physicians and nephrologists. Am J Med 110: 499-500, 2001.
3. Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. Immunomodulation with low-dose immunoglobulins for moderate IgAN and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 69: 327-334, 1995.
4. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 4: CD003965, 2003.
5. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 16: 2088-2097, 2005.
6. Floege J, Eitner F. Present and future therapy options in IgA nephropathy. J Nephrol 18: 354-361, 2005.
7. Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan. 2nd version. Clin Exp Nephrol 7: 93-97, 2003.
8. Miura M, Endoh M, Nomoto Y, Sakai H. Long-term effect of urokinase therapy in IgA nephropathy. Clin Nephrol 32: 209-216, 1989.
9. Zhuang Y, Chen X, Zhang Y, Fu B, Cheng Q. The effect of urokinase treatment combined with angiotensin-converting enzyme inhibitor on IgA nephropathy: a clinical control study. J Fuzhou General Hospital 7: 12-16, 2000 (in Chinese, Abstract in English).
10. Chen X, Qiu Q, Tang L, et al. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy. Nephrol Dial Transplant 19: 852-857, 2004.
11. Wu R, Sun Y, Wang W. The effect of urokinase combined with sodium ferulate on IgA nephropathy. Sci Tech Engng 16: 2532-2534, 2006 (in Chinese, Abstract in English).
12. Yagame M, Tomino Y, Miura M, et al. Clinical effect of dipyridamole in patients with IgA nephropathy. Tokai J Exp Clin Med 11: 329-333, 1986.
13. Chan MK, Kwan SY, Chan KW, Yeung CK. Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. Am J Kidney Dis 9: 417-421, 1987.
14. Tojo S, Narita M, Hatano M, Miyahara T, Honda N, Orita Y. A double-blind controlled study of dipyridamole-perlongets and placebo in patients with chronic glomerulonephritis multi-clinical study. Jin to Toseki (Kidney and Dialysis) 22: 751-776, 1987 (in Japanese).
15. Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 36: 60-66, 1991.
16. Lee GSL, Choong HL, Chiang GSC, Woo KT. Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 3: 117-121, 1997.
17. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323: 42-46, 2001.
18. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomized controlled trials. BMJ 319: 670-674, 1999.
19. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412, 1995.
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, 1996.
21. Camara S, de la Cruz JP, Frutos MA, et al. Effects of dipyridamole on the short-term evolution of glomerulonephritis. Nephron 58: 13-16, 1991.
22. Chen X, Liu H, Wu J. The effect of long-term urokinase treatment combined with angiotensin-converting enzyme inhibitor on IgA nephropathy with glomerular sclerosis: a clinical control study [abstract]. J Am Soc Nephrol 12: 67A, 2001.
23. Liu H, Chen X, Tang L, Liu S, Qiu Q. follow-up of the effect of the urokinase combined with benazepril on IgA nephropathy. Chin J Nephrol 19: 199-204, 2003 (in Chinese, Abstract in English).
24. Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 10: 101-109, 1999.
25. Nolin L, Courteau M. Management of IgA nephropathy: evidence based recommendations. Kidney Int 70(Suppl.): S56-S62, 1999.
26. Strippoli GF, Manno C, Schena FP. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 41: 1129-1139, 2003.
27. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton) 9: 177-185, 2004.
28. Kawamura T. Treatment of IgA nephropathy: corticosteroids, tonsillectomy, and mycophenolate mofetil. Contrib Nephrol 157: 37-43, 2007.
29. Navaneethan SD, Viswanathan G, Strippoli GF. Meta-analysis of mycophenolate mofetil in IgA nephropathy. Nephrology (Carlton) 13: 90, 2008.
30. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 8: 1739-1744, 1997.
31. Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 10: 268-273, 2006.
32. Bergstein JM. Glomerular fibrin deposition and removal. Pediatr Nephrol 4: 78-87, 1990.
33. Glass WF, Radink RA, Garom JA, Kreisberg JI. Urokinasedependent adhesion loss and shape change after cyclic adenosinc monophosphate elevation in cultured rat mesangial cells. J Clin Invest 82: 1922-1936, 1988.
34. Takehara K, Igarashi A, Ishibashi Y. Dipyridamole specifically decreases platelet-derived growth factor release from platelets. Pharmacology 40: 150-156, 1990.
35. Nagase M, Kumagai H, Honda N. Suppression of proteinuria by dipyridamole in rats with aminonucleoside nephropathy. Ren Physiol 7: 218-226, 1984.
36. Gohda T, Makita Y, Shike T, et al. Effect of dilazep hydrochloride, an antiplatelet agent, on the proliferation of cultured mouse glomerular mesangial cells. Nephron 84: 90-91, 2000.
37. de long PE, van de Meer J, van de Hem GK, de Zeeuw D. Is the antiproteinuric effect of dipyridamole hemodynamically mediated? Nephron 50: 292-294, 1988.